Clinical Trials Browser

INDUSTRY × Carcinoma, Basal Cell × cemiplimab × Clear all

NCT03889912 2026-01-21

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Phase 1 Completed

97 enrolled

Dermatologic

Carcinoma, Basal Cell

NCT04916002 2025-12-05

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Phase 2 Terminated

77 enrolled 18 charts

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT06132191 2025-11-20

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Approved for marketing

DermatologicThoracic

Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung

NCT03836105 2025-10-15

CASE

Completed

287 enrolled

Dermatologic

Carcinoma, Basal Cell

NCT03132636 2025-04-08

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Phase 2 Completed

138 enrolled 21 charts 1 FDA

Dermatologic

Carcinoma, Basal Cell